Pharsight

Stribild generic

Stribild is an anti-HIV drug owned by Gilead Sciences Inc. This drug contains active ingredients such as Cobicistat, Elvitegravir, Emtricitabine, and Tenofovir Disoproxil Fumarate. It came into the market on 27 August, 2012, and is available in tablet for oral use. It has a total of 18 patents, none of which have expired yet.

When will Stribild generic be available?

The Stribild generic release date is predicted to be after 06 April, 2033. This is due to the expiry of the drug's last patent. However, it's important to note that generic release can be earlier due to what is known as a Para IV filing. This means a manufacturer can challenge the validity of a patent before it expires.

Stribild uses

Stribild is primarily used as a treatment for HIV infection. It uses a composition which contains a pharmacokinetic enhancer that inhibits the cytochrome P450 monooxygenase. This inhibition plays a crucial role in the treatment of HIV.

Stribild patent expiration

Stribild's patents encompass various aspects of its formulation and use. For instance, some patents concern 'Compositions and methods for combination antiviral therapy'. The final patent expiry, which could mark the possible release of the Stribild generic, is on the 06 April, 2033 for the patent titled 'Use of solid carrier particles to improve the processability of a pharmaceutical agent'. Below are the details of the patents:

EPO Oppostions filed on Stribild

Litigations filed on Stribild

Stribild dosage

Want to ask something?